An Open Letter from AmirAli Talasaz, co-CEO of Guardant Health

To Our Patients, Healthcare Providers, Partners, and Employees,

At Guardant Health, we are committed to bringing innovative and accurate cancer diagnostic tools to the world, always with the singular goal of improving patient outcomes. Recently, I issued a challenge to Kevin Conroy, CEO of Exact Sciences, regarding their recent colorectal cancer screening data. I understand this public action has caused confusion and even upset some cancer patients, advocates and others. I want to take a moment to clarify my intentions.

This challenge was not about corporate competition or industry rivalry. It was about something much more fundamental: providing transparent and high-quality scientific disclosures that ultimately benefit patients. 

Data in the pre-pivotal setting has been sometimes presented in ways that can obscure the true impact on patients. Subtle differences in how data is collected, analyzed, or reported can lead to confusion, leaving the audience unsure of what a test can truly deliver. Patients deserve better. 

At Guardant, we take this responsibility seriously as a member of the scientific community. That’s why I issued this challenge—to bring more accountability to the disclosed pre-pivotal data that so many rely on. I believe that only through rigorous validation and clear communication we can move the scientific field forward and empower patients and healthcare providers to make truly informed decisions.

At the end of the day, it’s not about any single company winning or losing, it is about advancing the field to bring a brighter future for patients. 

At the heart of everything we do is the unwavering belief that we can and must do better for patients. We applaud those that are improving patient care and advancing the boundaries of what is possible in clinical science. Together, we will continue to push boundaries and challenge the status quo to deliver the best possible outcomes for patients.

Stronger Together.

AmirAli